期刊文献+

玻璃体腔注射康柏西普联合小梁切除术及视网膜光凝治疗新生血管性青光眼 被引量:13

Intravitreal injection of combercept combined with trabeculectomy and retinal photocoagulation for neovascular glaucoma
下载PDF
导出
摘要 目的探讨康柏西普玻璃体腔内注射联合小梁切除术及视网膜光凝治疗新生血管性青光眼的疗效及安全性。方法对21例(21眼)玻璃体腔内注射康柏西普联合小梁切除术及视网膜光凝治疗新生血管性青光眼患者进行回顾性分析,通过常规眼科检查:视力、裂隙灯、房角镜、非接触眼压、彩色眼底照相以及眼底荧光血管造影(FFA)等,确诊患者为新生血管性青光眼。随后采用康柏西普玻璃体腔内注射联合小梁切除术及视网膜光凝方法对患者进行治疗,观察并对比患者术前、术后的视力和眼压。因被选患者术前视力差,主要观察治疗前、康柏西普玻璃体腔注射后1周、小梁切除术及视网膜光凝术后1、3、6个月眼压情况,采用单因素重复测量方差分析。结果治疗前眼压均值(46.5±5.2)mmHg(1kPa=7.5 mmHg),康柏西普玻璃体腔注射后1周眼压(35.4±4.4)mmHg,小梁切除术及视网膜光凝术后1、3、6个月眼压分别是(16.3±2.9)mmHg、(16.4±2.2)mmHg、(16.0±2.4)mmHg,术后1周、术后1个月眼压较治疗明显改善(F=127.72,P<0.01),差异具有统计学意义;治疗后1个月、3个月、6个月相比,差异无统计学意义。结论康柏西普玻璃体腔内注射联合小梁切除术及视网膜光凝治疗新生血管性青光眼能够有效降低眼压,保护残存视力,疗效安全可靠。 Objective To investigate the efficacy and safety of intravitreous injection of combercept combined with trabeculectomy and retinal photocoagulation for the treatment of neovascular glaucoma.Methods We performed a retrospective analysis of 21 patients(21 eyes)with neovascular glaucoma by intravitreous injection of combercept combined with trabeculectomy and retinal photocoagulation.Patients were diagnosed with neovascular glaucoma through routine ophthalmic examination,including visual acuity,slit lamp,gonioscopy,non-contact to intraocular pressure,color fundus photography,and fundus fluorescein angiography(FFA).Then intravitreous injection of combercept combined with trabeculectomy and retinal photocoagulation were used as the treatment.The implication of visual acuity and intraocular pressure were compared before and after the surgery.Due to poor vision of patients,intraocular pressure were mainly observed before treatment,1 week after intravitreal injection of combercept,1,3,and 6 months after the surgery of trabeculectomy and retinal photocoagulation.Then single factor repeated measurement were used to analyze the variance.Results Intraocular pressure was(46.5±5.2)mmHg(1 kPa=7.5 mmHg)before treatment,and intraocular pressure was(35.4±4.4)mmHg 1 week after the intravitreal injection of combercept.The intraocular pressure was(16.3±2.9)mmHg,(16.4±2.2)mmHg and(16.0±2.4)mmHg,at 1,3 and 6 months after trabeculectomy and retinal photocoagulation,respectively.The intraocular pressure(IOP)was significantly improved after 1 week and 1 month after operation(F=127.72,P〈0.01),which was statistically significant.The difference was not statistically significant at 1 month,3 months,and 6 months after treatment.Conclusion Combercept intravitreous injection combined with trabeculectomy and retinal photocoagulation for the treatment of neovascular glaucoma can effectively reduce intraocular pressure and protect residual vision.The curative effect is safe and reliable.
作者 张爱平 Zhang Aiping(Department of Ophthalmology,Nanyuan Hospital,Fengtai District,Beijing100076,China)
出处 《山西医药杂志》 CAS 2018年第15期1753-1755,共3页 Shanxi Medical Journal
关键词 康柏西普 小梁切除术 视网膜光凝 新生血管性青光眼 Combercept Trabeculeetomy Retinal photoeoagulation Neovascular glaucoma
  • 相关文献

参考文献2

二级参考文献44

  • 1王光洁,宋艳萍,黄震晞,高文东.二极管激光睫状体光凝的眼压变化和病理学表现[J].眼科新进展,2002,22(1):25-27. 被引量:16
  • 2李裕钦,薛雨顺,车选义,赵欣,韩碧琴.新生血管性青光眼的手术治疗[J].眼科新进展,2005,25(4):358-358. 被引量:45
  • 3李贞,倪卫杰.视网膜新生血管生物药物治疗研究进展[J].国际眼科杂志,2007,7(4):1119-1123. 被引量:17
  • 4Reis-Filho JS, Tutt AN. Triple negative tumours critical review [J]. Histopathology,2008,52( 1 ) : 108-118.
  • 5Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial resuhs[J].Ophthamlol Clin North Am,2006,19(3): 361-372.
  • 6Raftery J, Clegg A, Jones J, et al.Ranibizumab(Lucentis)versus bevacizumab (Avastin) : modelling cost effectiveness [ J ].Br J Oph- thalmol, 2007,91 (9) : 1244-1246.
  • 7Atmani K,Coscas F,Coscas G,et al. Pegaptanib sodium for oc- cult choroidal neovascularization in neovascular age-related mac- ular degeneration: a prospective case series [J]. Eye (Lond) , 2009,23(5) : 1150-1154.
  • 8Areva lo FJ, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal Bevacizum ab(Avastin)for diffuse diabetic maeular edema: Results from the Pan-American Collabora- tive Retina Study Group (PACORES) at 12-months Follow-Up [Jl. G raefes Areh Clin Exp Ophthamlol,2009,247(6):735-743.
  • 9Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration[J~. Arch Op hthamlol, 2007, 125(11): 1460-1469.
  • 10Vallance JH,Johnson B,MajidMA,et al. A randomized prospec- tive double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intra- vitreal ranibizumab monotherapy in the treatment of neovascu- lar age-related macular degeneration [J].Eye (Lond) , 2010, 24 (10) : 1561-1567.

共引文献37

同被引文献96

引证文献13

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部